Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Valion Bio, Inc.TIVC · Entity 8459 | Chief Scientific Officer | December 18, 2024 | December 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Valion Bio, Inc.
Report date December 18, 2024 · Filed December 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2034-12-17 | Direct | 225,000 |
Reported balance
After 2024-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-18 · Grant · Acquired 225,000 · Balance 225,000 F1: Each Restricted Stock Unit is convertible into one share of Common Stock. F2: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the Vesting Commencement Date, and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit is convertible into one share of Common Stock.
F2: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the Vesting Commencement Date, and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2024 Filed Dec 20, 2024 22:15 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantRestricted Stock Units · Derivative | 225,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-24-008901 · ownership.xml · derivative · entry 1 Gurfein Blake · CIK 0001891888 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2034-12-17 F1 · derivative.exercise_price: Each Restricted Stock Unit is convertible into one share of Common Stock. F2 · derivative.exercise_date: Fifty percent (50%) of the Restricted Stock Units will vest upon the one (1) year anniversary of the Vesting Commencement Date, and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date. Read SEC document |
| March 12, 2024 Filed Mar 22, 2024 22:49 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0000950170-24-035555 · ownership.xml · derivative · entry 1 Gurfein Blake · CIK 0001891888 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-03-11 F1 · derivative.exercise_date: The option vests as follows: (i) 50% on the first anniversary of the grant date and (ii) the remaining 50% in 12 equal monthly installments over the 12 months thereafter. Read SEC document |
| May 08, 2023 Filed May 10, 2023 22:43 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0000899243-23-012533 · doc4.xml · derivative · entry 1 Gurfein Blake · CIK 0001891888 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-05-07 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the 36 months thereafter. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 22:32 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001104659-22-014161 · tm225821d1_4.xml · derivative · entry 1 Gurfein Blake · CIK 0001891888 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2032-02-03 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the next 36 months. Read SEC document |
| December 14, 2021 Filed Dec 17, 2021 01:38 UTC | Valion Bio, Inc. TIVC · Entity 8459 | GrantEmployee Stock Option (Right to Buy) · Derivative | 82,500 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001104659-21-150714 · tm2135733d4_4.xml · derivative · entry 1 Gurfein Blake · CIK 0001891888 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2031-12-13 F1 · derivative.exercise_date: The option vests as follows: (i) 25% one year from the grant date, and (ii) the remaining 75% in equal monthly installments over the next 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.